NASDAQ$MRSN

Mersana Therapeutics Inc · Q1 2019 earnings

Q1 2019 earnings · · Investor relations

Headline financials

Total Revenue

$41M

Previous: $3.06M+1239.3%
EPS (adj)

$0.70

Previous: -$0.54+229.6%
Capital Expenditures

$372K

Previous: $267K+39.3%
Free Cash Flow

-$25.1M

Previous: -$17.7M-41.9%
Net Income

$21.9M

Previous: -$12.4M+276.6%
Gross Profit

$25.9M

Previous: -$9.19M+381.7%
Cash & Equivalents

$137M

Previous: $32.4M+324.3%
Total Assets

$149M

Previous: $116M+29.1%
Stock-Based Comp

$1.16M

Previous: $745K+56.2%

Revenue & EPS history

Mersana · Revenue · Quarterly

$41M

Q1 2019+1,239.3%vs Q1 2018
Beat estimate in 4 of 11 quarters(36%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 12 quarterly earnings reports

Historical avg

+1.4%

Avg return

Earnings day

+2.5%

Avg return

5 days after

+1.3%

Avg return

30 days after

47%

17 / 36 earnings

Positive

+38.9%

Q2 2022

Best reaction

-20.3%

Q1 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025
Q3 2025+2.4%+0.8%+3.0%
Q2 2025+11.6%+22.3%+18.6%
Q1 2025-18.5%-0.2%-3.6%
Q4 2024-8.3%+3.6%-36.7%
Q3 2024+14.5%-3.7%-1.8%
Q2 2024-13.4%-7.2%+25.2%
Q1 2024-20.3%-23.8%-37.4%
Q4 2023+27.4%+33.8%+4.8%
Q3 2023-6.5%-12.9%+46.8%
Q2 2023+0.0%+4.2%+6.7%
Q1 2023+8.9%+8.2%+16.4%
Q4 2022+7.0%+4.4%-26.3%
Q3 2022-11.0%
Q2 2022+38.9%
Q1 2022-11.2%
Q4 2021+14.4%
Q3 2021-1.1%
Q2 2021-2.1%
Q1 2021-5.3%
Q4 2020+7.7%
Q3 2020-4.2%
Q2 2020-1.9%
Q1 2020-3.1%
Q4 2019+3.5%
Q3 2019+7.0%
Q2 2019+2.3%
Q1 2019+14.3%
Q4 2018+4.0%
Q3 2018+7.5%
Q2 2018+0.0%
Q1 2018-3.7%
Q1 2016-8.9%
Q3 2016-4.5%
Q3 2017-5.1%
Q4 2016+3.9%
Q2 2016+3.9%
Q1 2017

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro